Lexaria Bioscience to begin oral weight‑loss drug study; shares up

Lexaria Bioscience

01/04/2026 14:38

** Shares of drug developer Lexaria Bioscience LEXX.O rise 5.1% to 82 cents

** Co says it will begin a new human study of oral semaglutide, the active ingredient used in Novo Nordisk's NOVOb.CO Wegovy for weight loss

** Semaglutide helps control appetite by mimicking a gut hormone; Lexaria is testing tablets and capsules taken by mouth instead of injections - LEXX

** Co says the five-week trial will compare its DehydraTECH-enhanced formulations with Novo's Wegovy tablets, focusing on safety and how well the drug is absorbed

** Co says the study, which is fully funded, will begin recruiting after ethics approval

** Says positive results could help draw interest from pharmaceutical partners

** As of last close, stock up ~27% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))